At Arthritis and Rheumatic Diseases Specialties, we continually contribute to the development of new protocols and treatments for diseases by participating in clinical research. Clinical research allows us to achieve two important goals: to help patients who need treatment options in the short term, and to contribute to the approval of better treatment protocols in the long term. The valuable information learned from a clinical research trial provides medical knowledge about the risks and benefits of medications which can make a difference in the care of future patients. Participating in clinical research also provides an opportunity for patients to receive the newest treatment options and to have additional care of attention from the clinical research medical staff.
If you or anyone you know has been diagnosed with an autoimmune disorder including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Ankylosing Spondylitis, Osteoarthritis, and Gout and may be interested in participating in a clinical research trial, please call the Research Department at 305-932-4295 to discuss the inclusion and exclusion criteria for participation in a clinical trial.
These links will take you to the description of the clinical trials being conducted currently in the office under the clinical trials.gov website. You can read about the specific trial and see the Inclusion/Exclusion criteria to see if you qualify to participate.
Systemic Lupus Erythematosus:
- Amgen – Protocol 20200234: A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus with Inadequate Response to Standard of Care Therapy (recruiting)
- AstraZeneca AB – Protocol D3465C00001: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus (recruiting)
- UCB Biopharma SRL – Protocol SL0043: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active Systemic Lupus Erythematosus (recruiting)
- Biogen – Protocol 230LE303: A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care (recruiting)
- Eli Lilly and Company – Protocol I4V-MC-JAHZ: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in patients with Systemic Lupus Erythematosus (ongoing)
- AbbVie – Protocol M19-130: A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus (ongoing)
- Bristol-Myers Squibb Research and Development – Protocol IM011021: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus (Pro00025742) (ongoing)
- Horizon – Protocol HZNP-KRY-405: A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate (recruiting)
Psoriatic Arthritis (PsA):
If you or anyone you know has been diagnosed with an autoimmune disorder including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Ankylosing Spondylitis and Gout and may be interested in participating in a clinical research trial, please call the Research Department at 305-652-6676 to discuss the inclusion and exclusion criteria for participation in a clinical trial